BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 8402636)

  • 21. The modulation by xanthines of the DNA-damaging effect of polycyclic aromatic agents. Part II. The stacking complexes of caffeine with doxorubicin and mitoxantrone.
    Piosik J; Zdunek M; Kapuscinski J
    Biochem Pharmacol; 2002 Feb; 63(4):635-46. PubMed ID: 11992631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
    Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
    Ji YB; Zhou JH; Zuo MX; You QD
    Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
    Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
    Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of drug-induced apoptosis in human leukemic cell line (HL-60)].
    Hara S; Tagawa Y; Ayabe H; Darzynkiwicz Z
    Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():393-9. PubMed ID: 9589041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM.
    Lin CK; Nguyen TT; Morgan TL; Mei RL; Kaptein JS; Kalunta CI; Yen CF; Park E; Zou HY; Lad PM
    Exp Cell Res; 1998 Oct; 244(1):1-13. PubMed ID: 9770343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
    Muscarella DE; Rachlinski MK; Sotiriadis J; Bloom SE
    Exp Cell Res; 1998 Jan; 238(1):155-67. PubMed ID: 9457068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro.
    Dalezis P; Geromichalos GD; Voyatzi S; Trafalis D; Athanassiou AE; Koutsilieris M; Papageorgiou A
    J BUON; 2006; 11(3):323-7. PubMed ID: 17309157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
    Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.
    Streltsov S; Oleinikov V; Ermishov M; Mochalov K; Sukhanova A; Nechipurenko Y; Grokhovsky S; Zhuze A; Pluot M; Nabiev I
    Biopolymers; 2003; 72(6):442-54. PubMed ID: 14587067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry.
    Nicklee T; Crump M; Hedley DW
    Cytometry; 1996 Nov; 25(3):205-10. PubMed ID: 8914817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro.
    Pantazis P; Early JA; Mendoza JT; DeJesus AR; Giovanella BC
    Cancer Res; 1994 Feb; 54(3):771-6. PubMed ID: 8306340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
    Winter S; Weller M
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA].
    Strel'tsov SA; Mikheĭkin AL; Grokhovskiĭ SL; Oleĭnikov VA; Kudelina IA; Zhuze AL
    Mol Biol (Mosk); 2002; 36(5):912-30. PubMed ID: 12391856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.
    Rodriguez CO; Gandhi V
    Cancer Res; 1999 Oct; 59(19):4937-43. PubMed ID: 10519407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
    Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.